

	Page 1 of 4
Patient Name:	
Date of Birth:	
Date of Diffi.	

CMC85044-001NS Rev. 2/2021

# Ferric Carboxymaltose (INJECTAFER) Infusion Therapy Plan

Baseline Patient Demographic
To be completed by the ordering provider.
Diagnosis:kq Body Surface Area:(m²)
□ NKDA - No Known Drug Allergies □ Allergies:
Therapy Plan orders extend over time (several visits) including recurring treatment.
Please specify the following regarding the entire course of therapy:
Duration of treatment: weeks months unknown
Treatment should begin:   as soon as possible (within a week)  within the month  **Plans must be reviewed / re-ordered at least annually. **
Tians must be reviewed / re-ordered at least annually.
ORDERS TO BE COMPLETED FOR EACH THERAPY
ADMIT ORDERS
☑ Height and weight
✓ Vital signs
Hypotension Defined Admit
□ Nursing communication
Prior to starting infusion, please determine the patient's threshold for hypotension as defined by the following parameters. This information will be needed in the event of an infusion reaction occurring.  Hypotension is defined as follows:  1 month to 1 year - systolic blood pressure (SBP) less than 70  1 year to 11 years - systolic blood pressure (SBP) less than 70 + (2 x age in years)  11 years to 17 years - systolic blood pressure (SBP) less than 90  OR any age - systolic blood pressure (SBP) drop of more than 30% from baseline.  Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.
NURSING ORDERS
Please select all appropriate therapy
IV START NURSING ORDERS
☐ Insert peripheral IV / Access IVAD
Place PIV if needed or access IVAD if available
☐ lidocaine 1% BUFFERED (J-TIP LIDOCAINE)
0.2 mL, INTRADERMAL, PRN
when immediate procedure needed when procedure will take about 1 minute patient / family preference for procedure
Administration Instructions: NOTE: Do not use this medication in patients with bleeding disorders, platelets ≤ 20,000, or in patients taking anticoagulants, when accessing implanted ports or using a vein that will be utilized for chemotherapy administration, nor for pre-term infants or neonates.
☐ lidocaine - prilocaine (EMLA) cream
TOPICAL, PRN
when more than 60 minutes are available before procedure when procedure will take more than 1 hour
patient / family preference for procedure
Administration Instructions: NOTE: In children < 3 months of age, or < 5 kg in weight, maximum application time is 1 hour.



	Page 2 of 4
Patient Name:	
Date of Birth:	

CMC85044-001NS Rev. 2/2021

## Ferric Carboxymaltose (INJECTAFER) Infusion Therapy Plan

### ORDERS TO BE COMPLETED FOR EACH THERAPY

	DERO TO BE COMM ELTER FOR EACH MERAL T					
NURSING ORDERS, CONTINUED						
<u> </u>						
☐ lidocaine with transparent dressing 4% kit TOPICAL, PRN ☐ when 20 - 30 minutes are available before proc ☐ patient / family preference for procedure ☐ Heparin flush	cedure	rill take more than 1 hour				
used with all central lines including IVADs, with the heparin flush	10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de - accessing the IVAD.  heparin flush 100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de -					
☐ Sodium chloride flush						
Sodium chloride flush 0.9% injection 1 - 20 mL, INTRAVENOUS, PRN, IV line flush  Sodium chloride - preserative free 0.9% injectio 1 - 30 mL, INTRAVENOUS, PRN, IV line flush	1 - 20 mL, INTRAVENOUS, PRN, IV line flush  Sodium chloride - preserative free 0.9% injection					
PRE-PROCEDURE LABS						
✓ Complete Blood Count with Differential Unit collect, baseline labs before 1st infusion and r	•	DEFER UNTIL:	DURATION: For 2 treatments			
▼ Transferrin Unit collect, baseline labs before 1st infusion and r	•	DEFER UNTIL:	DURATION: For 2 treatments			
✓ Total Iron Binding Capacity Unit collect, baseline labs before 1st infusion and r	Total Iron Binding Capacity INTERVAL: Every 6 weeks DEFER UNTIL: DURATION: For 2 treatments  Unit collect, baseline labs before 1st infusion and repeat labs in 6 weeks.					
Reticulocytes Unit collect, baseline labs before 1st infusion and r		DEFER UNTIL:	DURATION: For 2 treatments			
Ferritin Unit collect, baseline labs before 1st infusion and r	•	DEFER UNTIL:	DURATION: For 2 treatments			
▼ Retic Hemoglobin equivalent-Rectic-He Unit collect, baseline labs before 1st infusion and r	•	DEFER UNTIL:	DURATION: For 2 treatments			
INTRA-PROCEDURE						

#### ☑ Vital signs

Baseline vital signs (blood pressure, pulse, respiration, and temperature), then monitor vitals 5 minutes after initiation of infusion, at completion of infusion, then every 15 minutes until 30 minutes after infusion completed.



	Fage 3 01 4
Patient Name:	
Date of Birth:	
Date of Birtin.	

CMC85044-001NS Rev. 2/2021

## Ferric Carboxymaltose (INJECTAFER) Infusion Therapy Plan

#### ORDERS TO BE COMPLETED FOR EACH THERAPY

INT	RA-PROCEDURE, CONTINUED
☑	Perform pain assessment Assess pain prior to start of ferric carboxymaltose infusion.
$\overline{\mathbf{Q}}$	Physician communication order
	Please enter the dose of ferric carboxymaltose in 'mg' to facilitate prior authorization requirements.  < 50 kg: 15 mg / kg (Maximum of 750 mg)  >/= 50 kg: 750 mg  This mixture record is defaulted to a base of 100 mL sodium chloride 0.9%. Please indicate the desired volume if it is other than 100 mL:  mL
V	ferric carboxymaltose in sodium chloride 0.9% 100 mL infusion
	INTERVAL: 1 time a week DEFER UNTIL: DURATION: For 2 treatments  INTRAVENOUS, at 400 mL / hour, ONCE, administer over 15 minutes. Dose must be separated by at least 7 days. Administer over a minimum of 15 minutes. Monitor vital signs (including blood pressure); signs and symptoms of hypersensitivity (monitor for ≥ 30 minutes following the end of administration and until clinically stable); monitor infusion site for extravasation.  Dose:mL
	erapy Appointment Request ase select department for the therapy appointment request:
Ехр	ires in 365 days
	☐ Dallas Special Procedures ☐ Plano Infusion Center ☐ Dallas Allergy ☐ Dallas Transplant ☐ Dallas Neurology
ΕN	TERGENCY MEDICATIONS
<b>I</b>	Nursing communication  1. Hives or cutaneous reaction only – no other system involvement PATIENT IS HAVING A DRUG REACTION:
	<ul> <li>a. Stop the infusion</li> <li>b. Give diphenhydramine as ordered</li> <li>c. Check heart rate, respiratory rate and blood pressure every 5 minutes until further orders from provider.</li> <li>d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation) if not already on one</li> <li>e. Notify provider for further orders</li> </ul>
	2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling PATIENT IS HAVING ANAPHYLAXIS:
	<ul> <li>a. Stop the infusion</li> <li>b. Call code – do not wait to give epinephrine</li> <li>c. Give epinephrine as ordered</li> <li>d. Notify provider</li> <li>e. Check heart rate, respiratory rate and blood pressure every 5 minutes until the code team arrives.</li> <li>f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.</li> <li>g. Give diphenhydramine once as needed for hives</li> <li>h. May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team arrives.</li> <li>i. May give albuterol as ordered for wheezing with oxygen saturation stable while waiting for code team, continue to monitor oxygen saturation.</li> <li>Hypotension is defined as follows:</li> </ul>
	1 month to 1 year – systolic blood pressure (SBP) less than 70 1 year to 11 years – systolic blood pressure (SBP) less than 70 + (2 x age in years) 11 years to 17 years – systolic blood pressure (SPB) less than 90 OR any age – systolic blood pressure (SPB) drop more than 30% from baseline. Baseline systolic blood pressure x 0.7 = value below defined as hypotension.



	Page 4 of 4
Patient Name:	
Date of Birth:	

CMC85044-001NS Rev. 2/2021

## Ferric Carboxymaltose (INJECTAFER) Infusion Therapy Plan

#### ORDERS TO BE COMPLETED FOR EACH THERAPY

EPINEPHrine Injection Orderable For Therapy Plan   (AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg   0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses   Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.   Dose:	EMERGENCY MEDICATIONS, CONTINUED			
(AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg  0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.  Dose:    Cardio / Respiratory Monitoring   Rationale for Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)   Cardio / Respiratory Monitoring: High risk patient (please specify risk)				
0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.    Dose:				
distress with desaturation until the code team arrives, for 3 doses Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.    Dose:	(AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg			
Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.    Dose:		anaphylaxis and may be	repeated for persist	ent hypotension and respiratory
Cardio / Respiratory Monitoring Rationale for Monitoring: High risk patient (please specify risk)    Clinically significant cardiac anomalies or dysrhythmias   Recent acute life-threatening event   Unexplained or acutely abnormal vital signs   Acute, fluctuating or consistent oxygen requirements   Monitor Parameters (select all that apply);   Heart rate   Oxygen saturation   Respiratory rate   diphenhydrAMINE injection   mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day.    Dose:		r a pH > 9, or an osmolalit	y > 600 mOsm / L.	
Rationale for Monitoring: High risk patient (please specify risk)    Clinically significant cardiac anomalies or dysrhythmias     Recent acute life-threatening event   Unexplained or acutely abnormal vital signs     Artificial airway (stent, tracheostomy, oral airway)     Acute, fluctuating or consistent oxygen requirements     Monitor Parameters (select all that apply):	Dose:		-	
Rationale for Monitoring: High risk patient (please specify risk)    Clinically significant cardiac anomalies or dysrhythmias     Recent acute life-threatening event   Unexplained or acutely abnormal vital signs     Acute, fluctuating or consistent oxygen requirements     Monitor Parameters (select all that apply):				
Clinically significant cardiac anomalies or dysrhythmias   Recent acute life-threatening event   Unexplained or acutely abnormal vital signs   Artificial airway (stent, tracheostomy, oral airway)   Acute, fluctuating or consistent oxygen requirements   Monitor Parameters (select all that apply):   Heart rate   Oxygen saturation   Respiratory rate   Telemetry Required:   Yes   No   Heart rate   Oxygen saturation   Respiratory rate   diphenhydrAMINE injection   1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day.   Dose:   Albuterol for aerosol   0.25 mg / kg, INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose   Dose:   POST - PROCEDURE   Warsing communication   Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion   INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose   Dose:   Gircle one):   MD	Cardio / Respiratory Monitoring	k)		
Unexplained or acutely abnormal vital signs   Artificial airway (stent, tracheostomy, oral airway)   Acute, fluctuating or consistent oxygen requirements   Monitor Parameters (select all that apply):   Heart rate   Oxygen saturation   Respiratory rate   Telemetry Required:   Yes   No     Heart rate   Oxygen saturation   Respiratory rate     Monitor Parameters (select all that apply):   Heart rate   Oxygen saturation   Respiratory rate     Respiratory rate   Respiratory rate     Respiratory rate   Re	☐ Clinically significant cardiac anomalies or dysrhythmias	<b>n</b> ) S		
Artificial airway (stent, tracheostomy, oral airway)   Acute, fluctuating or consistent oxygen requirements   Monitor Parameters (select all that apply):	☐ Recent acute life-threatening event			
Acute, fluctuating or consistent oxygen requirements   Monitor Parameters (select all that apply):   Heart rate   Oxygen saturation   Respiratory rate   Telemetry Required:   Yes   No   No   Heart rate   Oxygen saturation   Respiratory rate   Telemetry Required:   Yes   No   No   Heart rate   Oxygen saturation   Respiratory rate   Telemetry Required:   Yes   No   No   No   No   No   No   No   N	☐ Unexplained or acutely abnormal vital signs ☐ Artificial airway (stent, tracheostomy, oral airway)			
Telemetry Required:	☐ Acute, fluctuating or consistent oxygen requirements			
diphenhydrAMINE injection  1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day.  Dose:  Albuterol for aerosol  0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose  Dose:  POST - PROCEDURE  Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one):  MD DO		ygen saturation   □  Resp	iratory rate	
1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose maximum dose = 50 mg per dose, 300 mg per day.  Dose:	1.515.116.11) 1.154.116.11			
Dose:  Albuterol for aerosol  0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose  Dose:  POST - PROCEDURE    Nursing communication   Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.    Sodium chloride 0.9% infusion   INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose   Dose: (circle one):   MD	diphenhydrAMINE injection			
□ Albuterol for aerosol  0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose  Dose:  □ Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion.  Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD.  Discontinue PIV prior to discharge on the last day of infusion.  □ Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  □ (circle one):  MD DD		eaction, for 1 dose maximu	um dose = 50 mg pe	r dose, 300 mg per day.
0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose  Dose:    POST - PROCEDURE	Dose:			
saturation for 1 dose  Dose:  POST - PROCEDURE  Value Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one): MD DO	☐ Albuterol for aerosol			
POST - PROCEDURE  Nursing communication Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  Sodium chloride 0.9% infusion INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose Dose:  (circle one): MD DO		gen saturations stable wh	ile waiting for code	team, continue to monitor oxygen
POST - PROCEDURE   Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one): MD DO	_			
✓ Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  ✓ Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one): MD DO				
✓ Nursing communication  Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  ✓ Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one): MD DO				
Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.   Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:	POST - PROCEDURE			
Flush PIV or IVAD with 20 mL 0.9% sodium chloride at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.   Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:	Nursing communication			
Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue PIV prior to discharge on the last day of infusion.  Sodium chloride 0.9% infusion  INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one): MD DO	_	etion of the infusion		
INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one):  MD DO	Flush IVAD with saline and heparin flush per protocol prior to de-a	accessing IVAD.		
INTRAVENOUS, at 0 -25 mL / hr, ONCE, for 1 dose  Dose:  (circle one):  MD DO	Sodium chloride 0.9% infusion			
Dose:(circle one):  MD DO	—			
(circle one): MD DO	· · · · · · · · · · · · · · · · · · ·			
MD DO				
MD DO				
MD DO				
Signature of Provider Credentials Date Time				
	Signature of Provider	Credentials	Date	Time
	rinted Name of Provider			